POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized control trial in which each patient will be randomly
assigned to receive either extended half-life factor VIII based replacement therapy or
non-FVIII based replacement therapy, which are both standard of care treatment for persons
with Hemophilia A.